747412-64-2|Luminespib mesylate|3-Isoxazolecarboxamide, 5-(5-(1,1-dimethylethyl)-2,4-dihydroxyphenyl)-N-ethyl-4-(4-(4-morpholinylmethyl)phenyl)-, mesylate|-范德生物科技公司

Luminespib mesylate

NMR下载 COA and HPLC MSDS下载
names：
3-Isoxazolecarboxamide, 5-(5-(1,1-dimethylethyl)-2,4-dihydroxyphenyl)-N-ethyl-4-(4-(4-morpholinylmethyl)phenyl)-, mesylate
CAS号：
747412-64-2
MDL Number：
MF(分子式)： C28H37N3O8S MW(分子量)： 575.677
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Luminespib mesylate
英文别名	Luminespib mesylate; AUY922; AUY-922; AUY 922; NVP AUY922; NVP AUY-922; VER52296 ; VER-52296 ; VER 52296 ; Luminespib
CAS号	747412-64-2
SMILES	O=C(C1=NOC(C2=CC(C(C)(C)C)=C(O)C=C2O)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC.OS(=O)(C)=O
Inchi	InChI=1S/C27H33N3O5.CH4O3S/c1-5-28-26(33)24-23(18-8-6-17(7-9-18)16-30-10-12-34-13-11-30)25(35-29-24)19-14-20(27(2,3)4)22(32)15-21(19)31;1-5(2,3)4/h6-9,14-15,31-32H,5,10-13,16H2,1-4H3,(H,28,33);1H3,(H,2,3,4)
InchiKey	RDZQNOSWNDCPBS-UHFFFAOYSA-N
分子式 Formula	C28H37N3O8S
分子量 Molecular Weight	575.677
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Luminespib mesylate(CAS:747412-64-2 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Luminespib, also known as AUY-922, NVP-AUY922, VER52296, is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.13[1] Epub 2017 Dec 13. PubMed PMID: 29247830.

[2]Wang CY, Guo ST, Croft A, Yan XG, Jin L, Zhang XD, Jiang CC. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922. Mol Carcinog. 2018 Feb;57(2):284-294. doi: 10.1002/mc.22755. Epub 2017 Nov 14. PubMed PMID: 29068469.

[3] Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, Kim SW, Koh GY, Park KS, Lee DH. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Lett. 2017 Dec 28;411:19-26. doi: 10.1016/j.canlet.2017.09.040. Epub 2017 Oct 4. PubMed PMID: 28987383.

[4] Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells. Tumour Biol. 2017 Oct;39(10):1010428317722068. doi: 10.1177/1010428317722068. PubMed PMID: 28982310.

[5] Park KS, Yang H, Choi J, Seo S, Kim D, Lee CH, Jeon H, Kim SW, Lee DH. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer. Cancer Lett. 2017 Oct 10;40

6:47-53. doi: 10.1016/j.canlet.2017.07.028. Epub 2017 Aug 7. PubMed PMID: 28797845.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开